SCHEMBL21979404

SCHEMBL21979404

c1ccc2oc(N3CCOCC3)nc2c1

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ELANE P08246 1/20 0.63
ALDH1A1 P00352 1/20 0.56
POLB P06746 1/20 0.56
PRKDC P78527 2/20 0.55
XRCC6 P12956 1/20 0.54
XRCC5 P13010 1/20 0.54
SORD Q00796 2/20 0.53
GAA P10253 1/20 0.52
KMT2A Q03164 1/20 0.52
LMNA P02545 3/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
HTT P42858 2/20 0.50
MAPT P10636 2/20 0.50
CHRNA7 P36544 1/20 0.50
HTR3A P46098 1/20 0.50
FAAH O00519 1/20 0.50
TSHR P16473 1/20 0.50
KDM4E B2RXH2 1/20 0.49
HCAR2 Q8TDS4 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30903262 0.86 ELANE (0.57) ELANESORDGAAKMT2ALMNA
SCHEMBL31472604 0.86 ELANE (0.61) ELANEALDH1A1SORDGAAKMT2A
SCHEMBL5021493 0.86 ELANE (0.61) ELANEALDH1A1SORDGAAKMT2A
SCHEMBL1981175 0.84 ELANE (0.62) ELANEALDH1A1SORDGAAKMT2A
SCHEMBL1713373 0.84 SORD (0.55) ELANESORDGAAKMT2ALMNA
SCHEMBL5021503 0.84 ELANE (0.62) ELANEALDH1A1SORDGAAKMT2A
SCHEMBL2624458 0.84 SORD (0.58) ELANESORDGAAKMT2ALMNA
SCHEMBL31473673 0.83 LMNA (0.57) ALDH1A1SORDGAAKMT2ALMNA
SCHEMBL2201069 0.83 CHRNA7 (0.54) ELANESORDGAAKMT2ALMNA
SCHEMBL195554 0.81 HTR6 (0.53) ELANEALDH1A1SORDGAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025906-A1 KINASE MODULATORS AND METHODS OF USE THEREOF SUNDANCE BIOSCIENCES, INC. 2024-01-25 US disclosed
US-20220127263-A1 Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates AC IMMUNE SA (CH) 2022-04-28 US disclosed
US-20210371992-A1 ELECTROCHEMICAL ORGANIC REACTION SETUP AND METHODS PIRAMAL PHARMA LIMITED (IN) 2021-12-02 US disclosed
US-11136317-B2 NADPH oxidase 4 inhibitors ACTELION PHARMACEUTICALS LTD (CH) 2021-10-05 US disclosed
US-20200165235-A1 NADPH OXIDASE 4 INHIBITORS ACTELION PHARMACEUTICALS LTD (CH) 2020-05-28 US disclosed
CN-103333131-A Preparation method of 2-aminobenzoxazole compound SUZHOU OST ADVANCED MATERIALS CO LTD 2013-10-02 CN disclosed
CN-102596958-A 2' -fluoro CARBA-nucleoside analogs for antiviral treatment GILEAD SCIENCES INC 2012-07-18 CN disclosed
CN-101326454-B Method for manufacturing polarizing plate, polarizing plate and liquid crystal display device KONICA MINOLTA OPTO INC 2010-11-03 CN disclosed
CN-101326454-A Method for manufacturing polarizing plate, polarizing plate and liquid crystal display device KONICA MINOLTA OPTO INC (JP) 2008-12-17 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220127263-A1 Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates MAPT, MAP1LC3A, MAP1LC3B ELANE 3545/4885ALDH1A1 3543/4885POLB 2923/4885
US-20200165235-A1 NADPH OXIDASE 4 INHIBITORS NOX4, NOX1, CYBB ELANE 428/4885ALDH1A1 176/4885POLB 1792/4885
US-11136317-B2 NADPH oxidase 4 inhibitors NOX4, NOX1, CYBB ELANE 428/4885ALDH1A1 176/4885POLB 1792/4885
US-20240025906-A1 KINASE MODULATORS AND METHODS OF USE THEREOF TYK2, JAK1, JAK3 ELANE 4593/4885ALDH1A1 4807/4885POLB 3568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.